Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: EXPAREL 266 mg Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Extended Release Local Anesthetic for Postsurgical Pain After Posterior Colporrhaphy and Perineorrhaphy

NCT03875664
View directory record Official record
Conditions
Postoperative Pain
Interventions
Liposomal bupivacaine, Placebo - injection
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 25, 2026, 10:17 PM EDT
Terminated Phase 4 Interventional Results available

Phase 4, Controlled Study in Adult Subjects Undergoing Primary, 1-2 Level, Open Lumbar Spinal Fusion Surgery

NCT03015961
View directory record Official record
Conditions
Postoperative Pain Management
Interventions
EXPAREL and bupivacaine HCl, Bupivacaine HCl
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
15
States / cities
Gilbert, Arizona • Phoenix, Arizona • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 25, 2026, 10:17 PM EDT
Terminated Phase 4 Interventional Results available

Exparel vs. Standard Bupivicaine for Abdominoplasty

NCT01853176
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Liposomal Injection Bupivacaine (Exparel), Standard bupivicaine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Oct 25, 2026, 10:17 PM EDT
Terminated Phase 4 Interventional Results available

Analgesic Efficacy of Liposomal Bupivacaine vs. Bupivacaine HCL as a Tap Block After Abdominally Based Autologous Breast Reconstruction

NCT02662036
View directory record Official record
Conditions
Mammaplasty
Interventions
Bupivicaine HCL, Liposomal bupivacaine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 25, 2026, 10:17 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

A Comparison of Exparel to Bupivacaine in TAP Block for Abdominal Gynecologic Surgery

NCT03304444
View directory record Official record
Conditions
Gynecologic Cancer, Post Operative Pain
Interventions
Bupivacaine, liposomal bupivacaine
Drug
Lead sponsor
Abington Memorial Hospital
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Abington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Oct 25, 2026, 10:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections

NCT03176459
View directory record Official record
Conditions
C-Section, Pain Management
Interventions
Exparel + Bupivacaine, Bupivacaine
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
12
States / cities
Loma Linda, California • Stanford, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 25, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty

NCT02713178
View directory record Official record
Conditions
Pain
Interventions
bupivacaine liposome injectable suspension, Placebo
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
14
States / cities
Mobile, Alabama • Englewood, Colorado • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 25, 2026, 10:17 PM EDT
Completed Phase 4 Interventional Results available

Pain Management in Response to Exparel vs. Standard Bupivicaine

NCT02499159
View directory record Official record
Conditions
Pain
Interventions
Liposomal Bupivicaine, 0.25% standard bupivicaine
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 25, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Thoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic Surgery

NCT04117074
View directory record Official record
Conditions
Surgery, Analgesia
Interventions
Liposomal bupivacaine, Thoracic epidural analgesia (bupivacaine)
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 25, 2026, 10:17 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Long-acting Local Vaginal Cuff Anesthesia Following Hysterectomy

NCT07842159
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Combined Bupivacaine and Exparel, Normal Saline (NS)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

Multicenter Study for Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL

NCT03682302
View directory record Official record
Conditions
Postoperative Pain Management
Interventions
Exparel, 0.5% Bupivacaine HCl
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
6 Years to 17 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
17
States / cities
Loma Linda, California • Sacramento, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 25, 2026, 10:17 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Total Knee Arthroplasty

NCT02284386
View directory record Official record
Conditions
Pain
Interventions
Bupivacaine SNB, EXPAREL Infiltration
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Sheffield, Alabama • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 25, 2026, 10:17 PM EDT
Completed Phase 2 Interventional Results available

Parasternal Nerve Block in Cardiac Patients

NCT01826851
View directory record Official record
Conditions
Coronary Artery Disease, Pain, Postoperative
Interventions
Exparel, Placebo
Drug
Lead sponsor
Peter A Knight
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 25, 2026, 10:17 PM EDT
Terminated Phase 4 Interventional Results available

The Effect of EXPAREL® on Postsurgical Pain, and the Use of Narcotics

NCT03290196
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
EXPAREL 1.3 % in 20 ML Injection
Drug
Lead sponsor
Andrews Research & Education Foundation
Other
Eligibility
18 Years to 72 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Gulf Breeze, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 25, 2026, 10:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Exparel Use in Bilateral TAP Blocks for Postoperative Pain Control

NCT03878888
View directory record Official record
Conditions
Postoperative Pain, Surgery, Anesthesia, Local
Interventions
Exparel 266 MG Per 20 ML Injection
Drug
Lead sponsor
St. Luke's Hospital, Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 25, 2026, 10:17 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy of Rectal Infiltration of Exparel for Analgesic Benefit Following Hemorrhoidectomy

NCT02104414
View directory record Official record
Conditions
Hemorrhoid
Interventions
Exparel, Bupivacaine HCl with Epinephrine, Normal Saline
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
21 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 25, 2026, 10:17 PM EDT
Enrolling by invitation Phase 4 Interventional

Pilot Study on EXPAREL as an Intra-articular Posteromedial Surgeon Administered (IPSA) Block vs. Local Infiltration Analgesia in Knee Replacement Surgery

NCT07584915
View directory record Official record
Conditions
Total Knee Arthroplasty, Total Knee Arthroplasty Recovery
Interventions
Intra-articular Posteromedial Surgeon Administered (IPSA) Block with LIA, Local Infiltration Analgesia (LIA), Bupivacaine liposome injectable suspension (IPSA block), Bupivacaine liposome injectable suspension (LIA)
Procedure · Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 25, 2026, 10:17 PM EDT
Completed Phase 4 Interventional

Extended Delivery of Bupivacaine Study in Herniorrhaphy

NCT04102267
View directory record Official record
Conditions
Analgesia
Interventions
Bupivacaine liposome injectable suspension, Bupivacaine HCl without epinephrine via continuous infusion
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 25, 2026, 10:17 PM EDT
Suspended Phase 4 Interventional

Liposomal Bupivacaine in One-level Instrumented Posterior Spinal Fusion

NCT03745040
View directory record Official record
Conditions
Lumbar Spinal Stenosis, Lumbar Disc Herniation, Lumbar Disc Disease, Lumbar Spondylolisthesis
Interventions
Liposomal bupivacaine
Drug
Lead sponsor
Allina Health System
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 25, 2026, 10:17 PM EDT
Completed Phase 4 Interventional Results available

Liposomal Bupivacaine (Exparel) for Postoperative Pain Control for Open and Laparoscopic Abdominal Hernia Repair

NCT02128646
View directory record Official record
Conditions
Pain
Interventions
EXPAREL, Ketorolac, laparoscopic abdominal hernia repair, an open surgery for abdominal hernia repair
Drug · Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 25, 2026, 10:17 PM EDT
Not listed Phase 4 Interventional

Liposomal Bupivacaine Intercostal Nerve Block vs Thoracic Epidural for Regional Analgesia in Multiple Rib Fractures

NCT03574376
View directory record Official record
Conditions
Trauma, Trauma Injury, Pain, Acute
Interventions
Bupivacaine Liposome Injection, Bupivacaine
Drug
Lead sponsor
Chadrick Evans
Other
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 25, 2026, 10:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Liposomal Bupivacaine on Post Operative Pain and Narcotic Use After Bariatric Surgery

NCT03196505
View directory record Official record
Conditions
Bariatric Surgery Candidate, Pain, Postoperative
Interventions
Exparel 266 MG Per 20 ML Injection, Bupivacaine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 25, 2026, 10:17 PM EDT
Recruiting Phase 4 Interventional

Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy

NCT05224089
View directory record Official record
Conditions
Bowel Disease
Interventions
Liposomal Bupivicaine/Bupivacaine Admixture, Bupivacaine HCL
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 25, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics Study of Redosing EXPAREL in Healthy Volunteers

NCT02210247
View directory record Official record
Conditions
Healthy Volunteers
Interventions
EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 25, 2026, 10:17 PM EDT